OBJECTIVES: Vasopressor-induced vasoconstriction may compromise @entity8 in @entity1 with @entity326 , resulting in secondary organ failures. The authors compared the effects of the vasodilatatory agent @entity19642 against renal-dose @entity935 and placebo in @entity1 with @entity1063 therapy and @entity326 , using 24-hour serum @entity1011 clearance (C(crea)) as a major endpoint. The primary hypothesis to be tested was that @entity19642 is more effective than @entity935 and that @entity935 shows better effects than placebo regarding organ failures and C(crea). DESIGN: A prospective, randomized, controlled, double-blinded study. SETTING: Intensive care unit in a tertiary care university hospital. @entity1 : Sixty-one @entity1 with @entity326 defined according to established criteria. INTERVENTIONS: @entity1 received either @entity19642 (2 microg/kg/min, n = 20), @entity935 (3 microg/kg/min, n = 21), or placebo (n = 20). RESULTS: The trial groups were similar in terms of baseline characteristics. The authors found no significant differences among the @entity19642 , @entity935 , and placebo groups with regard to a comprehensive number of renal function parameters including C(crea) and organ-failure scores. There was a significant increase in heart rate after @entity19642 infusion; other hemodynamic parameters remained unchanged in the @entity19642 group. In a post hoc analysis that included only @entity1 with @entity8 at study inclusion (n = 28), @entity1 who received @entity935 showed significant improvements in C(crea) when compared with placebo. @entity19642 was not effective in this subgroup. CONCLUSIONS: @entity19642 is no more effective than @entity935 or placebo regarding renal function in @entity1 with @entity326 requiring @entity1063 . Both therapies do not influence organ-failure scores.

Comparison of systemic and renal effects of @entity19642 and @entity935 in @entity1063 -treated XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PARTICIPANTS'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment', 'renal and splanchnic blood flow'] @entity19642 :: ('MESH:C046318', 'Chemical') :: ['dopexamine', 'Dopexamine'] @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']
@entity326 :: (MESH:D012772,Disease) :: ['septic shock']
